Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and admin

Change in fair value of acquisition consideration

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Twist Bioscience Corp

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. Its products include genes, oligo pools, Next Generation Sequencing (NGS), variant libraries, synthetic controls, antibody discovery, and SARS-CoV-2 Tools. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Twist Bioscience Corp meets Q1 expectations, eyes growth opportunities

Twist Bioscience Corp's Q1 performance met or exceeded expectations across key revenue segments, with a focus on expanding customer base and improving turnaround times.
While facing challenges such as COVID impact on China sales and margin dips due to fixed costs, the company aims for revenue growth and improved margins through strategic execution.
The company's strengths lie in strong gross margins, record bookings in NGS, and efforts towards DNA data storage alliances, positioning for future growth and innovation.
Opportunities include continued customer expansion, Fast Gene market development, and revenue growth driven by NGS and SynBio performance, amidst a value-based pricing strategy.

Twist Bioscience Corp achieves $60.2M revenue in Q2 2023

Twist Bioscience Corp's Q2 2023 earnings call highlighted strong revenue growth, cost reduction efforts, and a focus on achieving profitability. The company is navigating challenges in the biopharma sector while leveraging strengths in technology and sales execution for future growth.

Twist Bioscience Corp reports record Q3 revenue, focuses on growth

Twist Bioscience Corp delivered a strong performance in Q3, with record revenue and strategic product launches driving growth across key segments.
While facing challenges in biopharma revenue and commercial execution, the company is focused on expansion, talent acquisition, and cost management to drive future growth.
With a clear focus on innovation, market expansion, and achieving profitability milestones, Twist Bioscience Corp is well-positioned for future success and market leadership.
The company's strengths in SynBio products, strategic market positioning, and stable funding outlook underscore its potential for sustained growth and value creation.

Twist Bioscience Corp reports robust revenue growth and eyes profitability

Twist Bioscience Corp's Q4 2023 earnings call highlighted strong revenue growth, operational efficiency, and a solid financial position.
The company faces challenges in managing expenses and achieving profitability but sees opportunities in revenue growth and market expansion.
By leveraging strengths in product launches, customer relationships, and revenue growth, Twist Bioscience aims for continued success and margin expansion in fiscal 2024.

Twist Bioscience Corp excels in Q1 2024, focuses on growth

Twist Bioscience Corp's Q1 2024 earnings call highlighted robust revenue growth, margin expansion, and strategic focus on operational efficiency. The company's emphasis on customer needs, premium pricing, and cost efficiency positions it well for future growth and profitability.

Twist Bioscience reports robust Q2 revenue growth and margin targets

Twist Bioscience Corp delivered strong revenue growth and aims for margin improvement, driven by successful product lines and strategic initiatives.
While facing challenges in managing expenses and achieving profitability, the company is well-positioned to leverage market opportunities and regulatory advantages.
With a focus on innovation, market expansion, and margin growth, Twist is poised for continued success and competitive growth in the biopharma sector.
Navigating operational challenges and seizing growth opportunities will be crucial for Twist Bioscience to achieve its financial targets and sustain market leadership.

Twist Bioscience Corp reports robust Q3 revenue growth and profitability outlook

Twist Bioscience Corp delivered strong revenue growth and operational performance in Q3 2024, driven by robust NGS and biopharma revenue streams.
While facing challenges in achieving profitability targets, the company's focus on margin improvement and capacity expansion positions it for future growth.
Guidance for fiscal 2024 indicates promising revenue growth, highlighting opportunities for sustained expansion and enhanced financial performance.

Twist Bioscience Corp reports record revenue and aims for profitability

Twist Bioscience Corp delivered strong financial performance, with record revenue and margin growth driven by key product segments and operational efficiencies.
The company's focus on achieving adjusted EBITDA profitability and cash flow positivity, along with robust fiscal 2025 guidance, signals a path towards sustainable growth.
While challenges like cost management and market competition persist, opportunities in market traction, revenue diversification, and innovation position the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

SAN FRANCISCO--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the presentation of new customer and company data generated using the Twist Bioscience target enrichment and library preparation products for next-generation sequencing (NGS). “The data presented at ASHG highlight the diverse applications of our NGS target enrichment technology which ca

Twist Bioscience Showcases Next-Generation Sequencing Presentations at Virtual American Society for Human Genetics 2020 Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (Nasdaq: TWST) and Beyond Earth, an artist collective, today announced a project to store high-resolution artworks in DNA to be launched to low Earth orbit and the Moon. Beyond Earth artists that will contribute work to the project include: Elena Soterakis, New York, NY; Richelle Gribble, Los Angeles, CA; and Yoko Shimizu, Linz, Austria and Tokyo, Japan. In the ‘To Space, From Earth' Capsule, select artworks made by memb

Twist Bioscience Collaborates With Beyond Earth to Launch Artwork Stored in DNA Into Space

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will host a Twist Biopharma Analyst & Investor Event on Friday, October 23, 2020. The event is scheduled to take place from 11:00 a.m. – 1:00 p.m. ET in a virtual format. The event will include an overview of Twist Biopharma and its unique approach to antibody

Twist Bioscience to Host Virtual Biopharma Analyst & Investor Event on October 23, 2020

SOUTH SAN FRANCISCO, Calif. & AMSTERDAM & NEW YORK--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Neogene Therapeutics, Inc., a biotechnology company pioneering a new class of fully personalized T cell therapies to treat cancer, today announced a broad strategic partnership. The companies will leverage Neogene’s proprietary expertise in targeting tumor neo-a

Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its CEO and co-founder, Emily M.

Emily Leproust, Ph.D., to Receive 2020 Rosalind Franklin Award

Twist Bioscience: New Profitability Oriented Management & Direction Compensates For The 435% Share-Premium

Company has 9 new partnerships in first 9 months against a goal of 5-10 in the fiscal year.

Twist Bioscience: Growth Play In Synthetic Biology

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #COVID19--Twist Bioscience Corporation (Nasdaq: TWST) today announced data demonstrating the potent neutralizing effects of multiple potential therapeutic antibodies, both Immunoglobulin G (IgG) antibodies and substantially smaller single domain VHH “nanobodies,” against SARS-CoV-2, the virus that causes COVID-19.

Twist Bioscience Announces Potent SARS-CoV-2 Neutralizing Data from COVID-19 Therapeutic Antibody Program

The DNA synthesis leader is rapidly expanding its product offerings, but losses continue to grow. Maybe it doesn't matter after all.

Twist Bioscience Is Rapidly Growing Its Customer Base. Can It Turn a Profit?

Twist Bioscience Corporation (TWST) CEO Emily Leproust on Q3 2020 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the third quarter of fiscal 2020, ended June 30, 2020.

Twist Bioscience Reports Third Quarter Fiscal 2020 Financial Results

Can the company possibly live up to its lofty market valuation?

What to Watch When Twist Bioscience Reports Fiscal Q3 Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Seismic Bio, Inc.

Seismic Bio Partners With Twist Bioscience for Discovery and Optimization of Antibodies

Twist Bioscience (TWST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Twist Bioscience (TWST) Report Negative Q3 Earnings? What You Should Know

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2020 third quarter ended June 30, 2020, following the close of market on Thursday, August 6, 2020.

Twist Bioscience to Report Fiscal 2020 Third Quarter Financial Results on Thursday, August 6, 2020

Twist Bioscience (NASDAQ: TWST) shares are trading higher on Tuesday after the company announced the launch of two coronavirus antibody panels to expedite research for COVID-19.

Why Twist Bioscience's Stock Is Trading Higher Today

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the availability of two new SARS-CoV-2 antibody panels designed for research use only.

Twist Bioscience Launches Two SARS-CoV-2 Antibody Panels to Expedite Research for COVID-19

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Erin Smith to the newly created position of senior vice president of government affairs and public policy.

Twist Bioscience Appoints Erin Smith Senior Vice President, Government Affairs and Public Policy

The company's $2.7 billion valuation is being driven by the coronavirus pandemic and federal stimulus. It doesn't appear sustainable.

Twist Bioscience Has Gained 186% in 2020. Is the Synbio Stock a Buy?

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #COVID19--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of its infectious disease product line with the addition of 16 new synthetic controls for the environmental testing, assay development, verification, and ongoing validation of diagnostic tests for a broad range of common respiratory diseases.

Twist Bioscience Launches Synthetic Controls for Respiratory Viruses

SOUTH SAN FRANCISCO, Calif. & BOSTON, Mass.

Twist Bioscience Partners with Invetx to Deliver Best-in-Class Antibody Therapeutics for Dogs and Cats

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #Antibodies--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its customer, Vanderbilt University Medical Center (VUMC) published positive preclinical results using potently neutralizing antibodies as a potential therapy for preventing and treating COVID-19 in humans. Twist Bioscience worked closely with VUMC to quickly supply a

Twist Bioscience Customer Vanderbilt University Medical Center (VUMC) Announces Publication of Positive Preclinical Results on Neutralizing Antibodies as a Potential Therapy for Preventing and Treating COVID-19

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #synbio--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a partnership with Takeda Pharmaceutical Company Limited (Takeda) for access to proprietary phage display libraries for the discovery, validation and optimization of antibodies in Takeda’s pipeline of biologics for oncology, rare diseases, neuroscience, and gastroenterolog

Takeda Partners with Twist Bioscience to Expand Biologics Discovery Capabilities

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the availability of the Twist Respiratory Virus Research Panel, a robust next-generation sequencing (NGS) approach to detecting a wide range of respiratory diseases including SARS-CoV-2, several other coronaviruses, influenzas, rhinoviruses and respiratory syncytial virus.

Twist Bioscience Adds Respiratory Virus Panel to Infectious Disease Product Line

Twist Bioscience Corporation (TWST) CEO Emily Leproust on Q2 2020 Results - Earnings Call Transcript

News for Twist Bioscience Corp Stock (TWST)